Loss of DUSP5 was associated with inferior clinical outcomes in patients with gastric and prostate cancer and re-expression of DUSP5 shrunk cell proliferation indices in various cancer cell lines [35]. This evidence concerns the gene DUSP5 and prostate cancer.